William Chin to lead PhRMA science & regulatory affairs
This article was originally published in Scrip
The Pharmaceutical Research and Manufacturers of America (PhRMA) has named Dr William Chin executive vice-president of science and regulatory affairs, effective 1 July 2013. Currently, Dr Chin is the executive dean for research at Harvard Medical School. At PhRMA, he will oversee the organization's scientific and regulatory affairs portfolio, including implementation of the Prescription Drug User Fee Act (PDUFA), clinical trials, and drug discovery and research collaboration. He will report to PhRMA president and CEO John Castellani and will also become a member of the PhRMA management committee.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.